8-K
filed March 18, 2025, 7:59 PM ET
CIK 0001966494
other material
confidence high
sentiment negative
materiality 0.85
CARGO Therapeutics, Inc.: restructuring charge — CARGO suspends all pipeline development, cuts 90% of workforce, appoints interim CEO to pursue reverse merger
CARGO Therapeutics, Inc.
- Board approves suspending CRG-023 and allogeneic platform; workforce reduced ~90%.
- Cash, cash equivalents and marketable securities total $368.1M as of Dec 31, 2024.
- Expected exit costs of $24M–$29M, majority recognized in H1 2025.
- CEO Gina Chapman departs May 19, 2025; CFO/COO Anup Radhakrishnan appointed interim CEO.
- Engaged TD Cowen as exclusive financial advisor to explore reverse merger or other strategic alternatives.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Gina Chapman departed as President and Chief Executive Officer at CARGO Therapeutics, Inc..
- Action
- leaving
- Role
- President and Chief Executive Officer
Exact text from the filing
Gina Chapman, the Company’s President, CEO and member of the board of directors will be leaving the Company effective May 19, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Ginna Laport departed as Chief Medical Officer at CARGO Therapeutics, Inc..
- Action
- leaving
- Role
- Chief Medical Officer
Exact text from the filing
Dr. Ginna Laport, the Company’s Chief Medical Officer ("CMO"), will be leaving the Company effective May 19, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Anup Radhakrishnan was appointed as Interim Chief Executive Officer at CARGO Therapeutics, Inc..
- Action
- appointed
- Role
- Interim Chief Executive Officer
Exact text from the filing
the Board appointed Anup Radhakrishnan, the Company’s Chief Financial Officer and Chief Operating Officer, to succeed Ms. Chapman as interim CEO.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 1.0
CARGO Therapeutics, Inc. announced a restructuring with charges of $24.0 million to $29.0 million (approximately 90%).
- Type
- restructuring
- Charge
- $24.0 million to $29.0 million
- Headcount
- approximately 90%
Exact text from the filing
combination, and engaged TD Securities (USA) LLC as the Company’s exclusive financial advisor. In connection with these actions, the Company expects to incur expenses of between $24.0 million to $29.0 million in total, a substantial portion of which we expect to recognize during the first half of 2025. The anticipated expenses include: severance, benefits, payroll
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.